Current Report Filing (8-k)
January 09 2023 - 07:02AM
Edgar (US Regulatory)
false 0001759138 0001759138 2023-01-09
2023-01-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
January 9, 2023
Date of Report (Date of earliest event reported)
CABALETTA BIO, INC.
(Exact name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware |
|
001-39103 |
|
82-1685768 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
|
|
|
2929 Arch Street, Suite
600, |
|
|
Philadelphia, PA |
|
19104 |
(Address of principal executive
offices) |
|
(Zip Code) |
(267) 759-3100
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of Each Class
|
|
Trading
Symbol(s)
|
|
Name of Each Exchange
on Which Registered
|
Common Stock, par value $0.00001 per share |
|
CABA |
|
The
Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 7.01 |
Regulation FD Disclosure.
|
On January 9, 2023, Cabaletta Bio, Inc. (the “Company”) posted
to the “Investors & Media” section of the Company’s
website at www.cabalettabio.com an updated
corporate presentation providing a corporate overview and updated
development plan (the “Corporate Presentation”). A copy of the
Corporate Presentation is attached hereto as Exhibit 99.1 and is
incorporated by reference into this Item 7.01 of this Current
Report on Form 8-K.
The information contained in Item 7.01 of this Current Report on
Form 8-K, including Exhibit
99.1 attached hereto, is being furnished and shall not be deemed to
be “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section and shall not be
incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly
set forth by specific reference in such filing.
Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned, hereunto duly
authorized.
|
|
|
|
|
|
|
|
|
|
|
CABALETTA BIO, INC. |
|
|
|
|
Date: January 9, 2023 |
|
|
|
By: |
|
/s/ Steven Nichtberger
|
|
|
|
|
|
|
Steven Nichtberger, M.D. |
|
|
|
|
|
|
President and Chief Executive
Officer |
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Mar 2023 to Mar 2023
Cabaletta Bio (NASDAQ:CABA)
Historical Stock Chart
From Mar 2022 to Mar 2023